A
Anil Lalwani
Researcher at University of Miami
Publications - 3
Citations - 244
Anil Lalwani is an academic researcher from University of Miami. The author has contributed to research in topics: Spinal cord injury & Expanded access. The author has an hindex of 2, co-authored 3 publications receiving 193 citations.
Papers
More filters
Journal ArticleDOI
Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.
William J. Feuer,Joyce C. Schiffman,Janet L. Davis,Vittorio Porciatti,Phillip Gonzalez,Rajeshwari D. Koilkonda,Huijun Yuan,Anil Lalwani,Byron L. Lam,John Guy +9 more
TL;DR: No serious safety problems were observed in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitochondrial disorder and additional study follow-up of these and additional participants planned for the next 4 years is needed to confirm these preliminary observations.
Journal ArticleDOI
Human Schwann cells exhibit long-term cell survival, are not tumorigenic and promote repair when transplanted into the contused spinal cord.
Johana C. Bastidas,Gagani Athauda,Gabriela De la Cruz,Wai Man Chan,Roozbeh Golshani,Yerko Berrocal,Martha Henao,Anil Lalwani,Chikato Mannoji,Mazen Assi,P. Anthony Otero,Aisha Khan,Alexander Marcillo,Michael D. Norenberg,Allan D. Levi,Patrick M. Wood,James D. Guest,W. Dalton Dietrich,Mary Bartlett Bunge,Damien D. Pearse +19 more
TL;DR: Findings show that HuSCs exhibit a favorable toxicity profile for up to 6 months after transplantation into the contused rat spinal cord, an important outcome for FDA consideration of their use in human clinical trials.
Journal ArticleDOI
The Interdisciplinary Stem Cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases
Aisha Khan,Michael A. Bellio,Ivonne Hernandez Schulman,Allan D. Levi,Bangon Longsomboon,Adriana E. Brooks,Krystalenia Valasaki,Darcy L. DiFede,Marietsy V. Pujol,Dileep R. Yavagal,Karen E. Bates,Ming-Sing Si,Sunjay Kaushal,Barth A. Green,Kimberly D Anderson,James D. Guest,Stephen Burks,Risset Silvera,Andrea J. Santamaria,Anil Lalwani,W. Dalton Dietrich,Joshua M. Hare +21 more
TL;DR: In this paper, the authors describe the use of the FDA's expanded access to investigational new drug (IND) to address rare and emergency conditions that include stiff-person syndrome, spinal cord injury, traumatic brain stem injury, complex congenital heart disease, ischemic stroke, and peripheral nerve injury.